HDECO: A method for Decreasing energy and cost by using virtual machine migration by considering hybrid parameters by Arash GhorbanniaDelavar (22563696)

“…<h2>Summary</h2><p dir="ltr">This research introduces <b>HDECO</b> (Hybrid Decreasing Energy and Cost Optimization) — a method designed to reduce both energy consumption and execution cost in cloud datacenters through intelligent virtual machine migration. …”

ANN architecture. by Abdelfattah Dani (22226715)

ANN architecture and configuration. by Abdelfattah Dani (22226715)

Illustration of BSC control using ANN for WECS. by Abdelfattah Dani (22226715)

Performance comparison between the OTC-FOC and ANN-BSC. by Abdelfattah Dani (22226715)

Training process flowchart of ANN-based MPPT controller. by Abdelfattah Dani (22226715)

Thematic clouds for lectures. by Ignacio García-Espona (21395335)

Displacement cloud maps. by Maogang Tian (21485116)

THD for the stator current i_sb (ANN-BSC). by Abdelfattah Dani (22226715)

ANN-BSC outcomes: (a) PMSG currents, (b) Zoom-in illustration. by Abdelfattah Dani (22226715)

Penalty conversions yield large practical decreases, but robustness and generalizability of result are limited by data quality and sample selection. by Ryan J. Treves (13527735)

Point cloud fusion instance effect. by Hongliang Zou (20707270)

“…<div><p>The study proposes a multi-sensor localization and real-timeble mapping method based on the fusion of 3D LiDAR point clouds and visual-inertial data, which addresses the issue of decreased localization accuracy and mapping in complex environments that affect the autonomous navigation of robot dogs. …”

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects: